Radionuclide-based theranostics — a promising strategy for lung cancer.
Purpose: This review aims to provide a comprehensive overview of the latest literature on personalized lung cancer management using different ligands and radionuclide-based tumor-targeting agents. Background: Lung cancer is the leading cause of cancer-related deaths worldwide. Due to the heterogenei...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 50; no. 8; pp. 2353 - 2375 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jul2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=164176956&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 164176956 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: Jul2023 vid: 50 iid: 8 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 164176956 162458557 10.1007/s00259-023-06174-8 164176956 ppf: 2353 ppct: 22 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Radionuclide-based theranostics — a promising strategy for lung cancer. aug: au: Zhu, Tianxing Hsu, Jessica C. Guo, Jingpei Chen, Weiyu Cai, Weibo Wang, Kai affil: Department of Respiratory Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, 322000, Yiwu, Zhejiang, China sug: ab: Purpose: This review aims to provide a comprehensive overview of the latest literature on personalized lung cancer management using different ligands and radionuclide-based tumor-targeting agents. Background: Lung cancer is the leading cause of cancer-related deaths worldwide. Due to the heterogeneity of lung cancer, advances in precision medicine may enhance the disease management landscape. More recently, theranostics using the same molecule labeled with two different radionuclides for imaging and treatment has emerged as a promising strategy for systemic cancer management. In radionuclide-based theranostics, the target, ligand, and radionuclide should all be carefully considered to achieve an accurate diagnosis and optimal therapeutic effects for lung cancer. Methods: We summarize the latest radiotracers and radioligand therapeutic agents used in diagnosing and treating lung cancer. In addition, we discuss the potential clinical applications and limitations associated with target-dependent radiotracers as well as therapeutic radionuclides. Finally, we provide our views on the perspectives for future development in this field. Conclusions: Radionuclide-based theranostics show great potential in tailored medical care. We expect that this review can provide an understanding of the latest advances in radionuclide therapy for lung cancer and promote the application of radioligand theranostics in personalized medicine. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|